meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs regorafenib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
COMMIT, 2022
randomized controlled trial
inadequate or absent control group
Phase 3 Number of pts targettted: 211
Lima C.
ASCO June 2022
10.1200/JCO.2022.40.16_suppl.TPS3647